Literature DB >> 17108979

Puzzling through fragment-based drug design.

Philip J Hajduk1.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 17108979     DOI： 10.1038/nchembio1206-658

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN： 1552-4450            Impact factor:   15.040


× No keyword cloud information.
  10 in total

1.  Drug discovery: A question of library design.

Authors:  Philip J Hajduk; Warren R J D Galloway; David R Spring
Journal:  Nature       Date:  2011-02-03       Impact factor: 49.962

2.  Fragment-based lead discovery: challenges and opportunities.

Authors:  Chaohong Sun; Andrew M Petros; Philip J Hajduk
Journal:  J Comput Aided Mol Des       Date:  2011-07-06       Impact factor: 3.686

Review 3.  Evolutions in fragment-based drug design: the deconstruction-reconstruction approach.

Authors:  Haijun Chen; Xiaobin Zhou; Ailan Wang; Yunquan Zheng; Yu Gao; Jia Zhou
Journal:  Drug Discov Today       Date:  2014-09-27       Impact factor: 7.851

4.  Fragment screening of infectious disease targets in a structural genomics environment.

Authors:  Darren W Begley; Douglas R Davies; Robert C Hartley; Thomas E Edwards; Bart L Staker; Wesley C Van Voorhis; Peter J Myler; Lance J Stewart
Journal:  Methods Enzymol       Date:  2011       Impact factor: 1.600

5.  Determination of ligand binding modes in weak protein-ligand complexes using sparse NMR data.

Authors:  Biswaranjan Mohanty; Martin L Williams; Bradley C Doak; Mansha Vazirani; Olga Ilyichova; Geqing Wang; Wolfgang Bermel; Jamie S Simpson; David K Chalmers; Glenn F King; Mehdi Mobli; Martin J Scanlon
Journal:  J Biomol NMR       Date:  2016-10-24       Impact factor: 2.835

6.  Rationalizing fragment based drug discovery for BACE1: insights from FB-QSAR, FB-QSSR, multi objective (MO-QSPR) and MIF studies.

Authors:  Prabu Manoharan; R S K Vijayan; Nanda Ghoshal
Journal:  J Comput Aided Mol Des       Date:  2010-08-26       Impact factor: 3.686

7.  Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors.

Authors:  Haitao Ji; Benjamin Z Stanton; Jotaro Igarashi; Huiying Li; Pavel Martásek; Linda J Roman; Thomas L Poulos; Richard B Silverman
Journal:  J Am Chem Soc       Date:  2008-03-06       Impact factor: 15.419

8.  One scaffold, three binding modes: novel and selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual screening.

Authors:  Chidochangu P Mpamhanga; Daniel Spinks; Lindsay B Tulloch; Emma J Shanks; David A Robinson; Iain T Collie; Alan H Fairlamb; Paul G Wyatt; Julie A Frearson; William N Hunter; Ian H Gilbert; Ruth Brenk
Journal:  J Med Chem       Date:  2009-07-23       Impact factor: 7.446

9.  ESR and X-ray Structure Investigations on the Binding and Mechanism of Inhibition of the Native State of Myeloperoxidase with Low Molecular Weight Fragments.

Authors:  Balagopalakrishna Chavali; Thierry Masquelin; Mark J Nilges; David E Timm; Stephanie L Stout; William F Matter; Najia Jin; Prabhakar K Jadhav; Gary G Deng
Journal:  Appl Magn Reson       Date:  2015-05-19       Impact factor: 0.831

10.  Development of Computational Approaches with a Fragment-Based Drug Design Strategy: In Silico Hsp90 Inhibitors Discovery.

Authors:  Roberto León; Jorge Soto-Delgado; Elizabeth Montero; Matías Vargas
Journal:  Int J Mol Sci       Date:  2021-12-08       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.